Navigation Links
Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors
Date:4/10/2008

Company's Board Expanded to Seven Members

DALLAS, April 10, /PRNewswire-FirstCall/ -- Crdentia Corp. (OTC Bulletin Board: CRDT), a leading healthcare staffing company, today said that its Board of Directors has elected David Jenkins and Raymond (Jay) Dunn to its Board of Directors, effective immediately. This announcement expands the Company's Board of Directors to seven members.

John Kaiser, Crdentia's President and Chief Executive Officer, said, "I am delighted David and Jay have joined Crdentia's Board of Directors. Each has tremendous depth of knowledge, healthcare expertise and public company experience that now can accrue to the benefit of Crdentia. With this announcement, the strength of our board is further enhanced, and we look forward to contributions from David and Jay as we continue our efforts to execute our strategic initiatives to improve Crdentia's operations and profitably grow our business."

Mr. Jenkins is currently the managing member and general partner of FatBoy Capital, LLC, a shareholder of Crdentia. In addition, Mr. Jenkins is also a Director of EP MedSystems, Inc. (Nasdaq: EPMD), a medical technology company that develops, manufactures and markets cardiac rhythm management and electrophysiology products, which are used to diagnose, monitor, visualize and treat irregular heartbeats known as arrhythmias. EP MedSystems, Inc. recently announced an agreement to be acquired by St. Jude's Medical, Inc. Mr. Jenkins has also served as President and a director of Transneuronix, Inc., a privately-held company engaged in the development of neuromuscular stimulation devices, until its sale to Medtronic Inc. in 2005. He is currently a director of Inset Technologies, Inc. and Catheter Robotics, Inc., both of which are privately held medical device companies.

Mr. Dunn is co-founder and Managing Director of the Latin Healthcare Fund (LHF), a shareholder of Crdentia, and Healthcare Investments International LLC (HII), which are US-based private equity investment groups that invests in healthcare companies. LHF and HII are affiliates of ACON Investments LLC, to identify healthcare investment opportunities in the U.S. Mr. Dunn also served on the Boards of Farmacias Ahumada, the largest pharmacy chain in Latin America and publicly traded in Chile; and Integramedica, the largest outpatient services company in Chile. Prior to LHF and HII, Mr. Dunn was Senior Investment Officer at Global Environment Fund where he managed the investment program for Latin America and served on company boards in Argentina, Chile, Peru and Colombia. He also sourced and analyzed investment opportunities in Eastern Europe and the Middle East. Mr. Dunn started his career with Brown Brothers Harriman & Co. as a banking officer in the Trade and Commodity Finance Group.

About Crdentia Corp.

Crdentia Corp., one of the nation's leading providers of healthcare staffing solutions, is focused on recruiting talented national and international healthcare professionals to meet the ever-increasing employment needs of over 2,300 clients. Crdentia is one of the few companies that can provide quality temporary staff for all healthcare industry positions including local nurses, travel nurses, allied health, locum tenens and home care professionals. For more information, visit http://www.crdentia.com.

Forward Looking Statements

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, a limited operating history with no earnings; reliance on the Company's management team, members of which have other business interests; the ability to successfully implement the Company's business plan; the ability to continue as a going concern; the ability to fund the Company's business and acquisition strategy; the growth of the temporary healthcare professional staffing business; difficulty in managing operations of acquired businesses; uncertainty in government regulation of the healthcare industry; and the limited public market for the Company's common stock. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. Crdentia undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Crdentia Corp.

John Kaiser, CEO

Phone: 972.850.0780

Fax: 972.392.2722

jkaiser@crdentia.com

Jim TerBeest, CFO

Phone: 972.850.0780

Fax: 972.392.2722

jterbeest@crdentia.com


'/>"/>
SOURCE Crdentia Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
2. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
3. Crdentias National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentias Travel Nurse Division
4. Crdentia Acquires ATS Health Services
5. Crdentia Announces Completion of $5M Financing
6. Crdentia Announces Appointment of Tim Jones to Senior Management Team
7. Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources
8. Crdentia Appoints Debbie Griffith to Director of Business Development, Reporting Directly to CEO
9. Crdentia Appoints Charlie Mayhone to Director of Operations for its National Travel Division and Charlotte, North Carolina Market
10. Crdentia Promotes Kevin Bollin to Area Manager of Austin, Dallas and San Antonio, Texas, Markets
11. Investor Insight Initiates Analyst Coverage on Crdentia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the ... use of health IT to create efficiencies in healthcare information exchange and a trusted ... 2017 Summer Forum which featured keynote addresses by Donald W. Rucker, MD, head ...
(Date:8/23/2017)... Ogden, Utah (PRWEB) , ... August 23, 2017 , ... ... 2013. , Give Back Day is a time Nightingale College dedicates to serving ... with organizations that thrive on donations and volunteers or those that need a little ...
(Date:8/23/2017)... ... August 23, 2017 , ... Boling Vision ... home to Indiana, and is now seeing patients at Boling Vision Center’s Elkhart ... in the diagnosis and treatment of eye disease, medical retina, high-technology cataract surgery, ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage ... - for Risk Management Solution Innovations and Security Solution for Government Innovations. Both ... in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , The ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing ... Relief with the 2017 Women’s Choice Award. The identification by women of an ... of 4 migraine sufferers are women. In a survey taken by the Women’s Choice ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: